NeuroNode By Control Bionics Wins US Reimbursement Approval

Control Bionics has revealed that the US Centers for Medicare & Medicaid Services (CMS) have given the green light to a new HCPCS code that designates the NeuroNode wireless sensor as eligible for reimbursement. Designed for individuals with degenerative neurological disorders, spinal cord injuries, cerebral palsy, and similar conditions that impair movement, the NeuroNode functions as a switch. It translates user movements into mouse clicks, enabling control over communication and software applications.

Unlike conventional input tools like joysticks and buttons, the NeuroNode leverages electromyographic signals and 3D spatial movements to offer precise control over devices used for speech generation, such as computers, phones, or tablets. This technology is particularly valuable for individuals who are unable to use traditional input methods, providing a groundbreaking solution for communication and device management.

With the introduction of HCPCS Level II code E2513, which classifies NeuroNode as an accessory for speech-generating devices and an electromyographic sensor, the device will be officially recognized as a durable augmentative and alternative communication tool. Starting in October, this new code will enable Control Bionics to secure a reimbursement of US$4,300 per unit, presenting a significant opportunity to expand their distribution network in the US.

Jeremy Steele, the CEO, highlighted that the new code will facilitate precise reporting of NeuroNode usage by healthcare providers. This advancement will streamline the claims process and improve patient access to the technology. He said, “While Control Bionics and its US customers have been reimbursed for the NeuroNode for many years, this has been done through a general ‘Accessories’ code, which resulted in reduced gross margins for the business. The introduction of this new code will allow for the direct billing of all components provided as part of our solutions. We expect that the separation of NeuroNode into its own code will result in increased sales through our existing channels.” He mentioned that the company plans to begin discussions with private insurers to have NeuroNode included as an in-network device under the new code.